Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Quipt Home Medical Corp and its officers or directors [1] Group 1: Investigation and Claims - Pomerantz LLP is conducting an investigation on behalf of investors of Quipt Home Medical Corp regarding possible securities fraud [1] - Investors are encouraged to contact Pomerantz LLP for more information about the investigation [1] Group 2: Shareholder Actions - Forager Capital Management, a major shareholder of Quipt, has requested the company to retract a misleading statement regarding its offer to acquire Quipt's shares at $3.10 each [3] - Following the press release from Forager, Quipt's stock price decreased by $0.18, or 8.53%, closing at $1.93 per share on June 5, 2025 [3] Group 3: Firm Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 85 years in fighting for victims of securities fraud [4] - The firm has successfully recovered numerous multimillion-dollar damages awards for class members [4]

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for alleged securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - The lawsuit involves claims that Organon and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Organon securities during the Class Period have until July 22, 2025, to request to be appointed as Lead Plaintiff [2]. Group 2: Financial Performance - On May 1, 2025, Organon reported a significant reduction in its dividend payout from $0.28 to $0.02, indicating a shift in capital allocation priorities [4]. - Following the announcement of the dividend cut, Organon's stock price dropped by $3.48 per share, or 26.91%, closing at $9.45 per share on the same day [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Caleres, Inc. and its officers or directors, following disappointing financial results and a significant stock price drop [1][2]. Financial Performance - Caleres reported first-quarter 2025 sales of $614.2 million, which is a 6.8% decline year-over-year, and acknowledged that this result was below expectations [2]. - The company suspended its guidance for 2025 due to uncertainty in the market environment [2]. - Following the announcement, Caleres's stock price fell by $3.00 per share, or 18.32%, closing at $13.38 per share on May 29, 2025 [2]. Legal Investigation - Pomerantz LLP is representing investors in investigating claims against Caleres for possible securities fraud [1]. - The firm has a long history in corporate and securities class litigation, having recovered significant damages for victims of securities fraud and corporate misconduct [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Quipt Home Medical Corp and its officers or directors [1] Group 1: Investigation and Claims - Pomerantz LLP is representing investors of Quipt Home Medical Corp in an investigation regarding possible securities fraud [1] - Forager Capital Management, a major shareholder of Quipt, has requested the company to retract a misleading statement related to its acquisition offer [2] Group 2: Stock Performance - Following the news of Forager's request, Quipt's stock price decreased by $0.18, or 8.53%, closing at $1.93 per share on June 5, 2025 [2]

Core Viewpoint - A class action lawsuit has been filed against DoubleVerify Holdings, Inc. for alleged securities fraud and unlawful business practices [2][3]. Company Performance - On February 28, 2024, DoubleVerify lowered its revenue growth expectations for Q1 2024, leading to a stock price drop of $8.35 per share, or 21.3%, closing at $30.89 on February 29, 2024 [3]. - On May 7, 2024, the company cut its full-year 2024 revenue outlook due to reduced ad spending from customers, resulting in a stock price decline of $11.79 per share, or 38.6%, closing at $18.78 on May 8, 2024 [4]. - On February 27, 2025, DoubleVerify reported lower-than-expected Q4 2024 sales and earnings, with a stock price drop of approximately 36%, closing at $13.90 on February 28, 2025 [5]. Market Research Findings - On March 28, 2025, Adalytics Research, LLC released a report claiming that DoubleVerify's advertisement verification services are ineffective, stating that customers are billed for ad impressions served to bots [6]. - The Wall Street Journal reported that DoubleVerify frequently fails to detect nonhuman traffic, contradicting the company's claims of helping brands avoid serving ads to bot accounts [6].

NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Eos Energy Enterprises, Inc. ("Eos" or the "Company") (NASDAQ: EOSE). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Eos and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On May 27, 2025, Eos ...

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of NWTN Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1] Group 1: Company Developments - On May 28, 2025, NWTN disclosed that it received a determination notice from Nasdaq, indicating that its securities would be delisted in accordance with listing rules [2] - Following this announcement, NWTN's stock price dropped by $0.72 per share, representing a 32% decline, closing at $1.53 per share on May 30, 2025 [2] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Quipt Home Medical Corp and its officers or directors [1] Group 1: Investigation and Claims - Pomerantz LLP is conducting an investigation on behalf of investors of Quipt Home Medical Corp regarding possible securities fraud [1] - Investors are encouraged to contact Pomerantz LLP for more information about the investigation [1] Group 2: Shareholder Actions - Forager Capital Management, a major shareholder of Quipt, has requested the company to retract a statement made on May 21, 2025, which they claim is false and misleading regarding an acquisition offer [3] - Following the press release from Forager, Quipt's stock price decreased by $0.18, or 8.53%, closing at $1.93 per share on June 5, 2025 [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Summit Therapeutics Inc. and its officers or directors following disappointing clinical trial results for its drug ivonescimab [1][3]. Group 1: Clinical Trial Results - On May 30, 2025, Summit announced topline results from the Phase III clinical trial, HARMONi, which evaluated ivonescimab [3]. - Patients treated with ivonescimab and chemotherapy were 48% less likely to progress or die compared to those receiving chemotherapy alone, but the drug did not show a statistically significant difference in overall survival [3]. Group 2: Stock Market Reaction - Following the announcement of the clinical trial results, Summit's stock price fell by $7.99 per share, representing a 30.5% decline, closing at $18.22 per share on May 30, 2025 [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Caleres, Inc. and its officers or directors, following disappointing financial results and a significant stock price drop [1][3]. Financial Performance - Caleres reported first-quarter 2025 sales of $614.2 million, marking a 6.8% decline year-over-year, which was acknowledged by the CFO as below expectations [3]. - The company suspended its guidance for 2025 due to uncertainty in the market environment [3]. - Following the financial report, Caleres's stock price decreased by $3.00 per share, or 18.32%, closing at $13.38 per share on May 29, 2025 [3]. Legal Investigation - Pomerantz LLP is actively investigating claims on behalf of investors regarding potential securities fraud by Caleres [1]. - The firm has a long history in corporate and securities class litigation, having recovered significant damages for victims of securities fraud and corporate misconduct [4].